Key result
1-month DAPT reduces bleeding with similar NACE and MACCE versus nonabbreviated DAPT in HBR MI patients.
Why the study?
The optimal duration of antiplatelet therapy after coronary stenting in patients at high bleeding risk presenting with an acute coronary syndrome remains unclear.
Does abbreviated antiplatelet therapy reduce bleeding and maintain ischemic safety compared to nonabbreviated therapy in high bleeding risk patients with acute or recent myocardial infarction after coronary stenting?
Does abbreviated antiplatelet therapy reduce bleeding and maintain ischemic safety compared to nonabbreviated therapy in high bleeding risk patients with acute or recent myocardial infarction after coronary stenting?
A 1-month DAPT strategy in high bleeding risk patients with acute or recent MI reduces bleeding without compromising ischemic outcomes compared to standard prolonged DAPT.
Answers are grounded in this paper and cite their sources.
Supports 1-month DAPT in high-bleeding-risk MI patients post-stenting; extends randomized evidence for abbreviated therapy to reduce bleeding.
BACKGROUND: The optimal duration of antiplatelet therapy (APT) after coronary stenting in patients at high bleeding risk (HBR) presenting with an acute coronary syndrome remains unclear. OBJECTIVES: The objective of this study was to investigate the safety and efficacy of an abbreviated APT regimen after coronary stenting in an HBR population presenting with acute or recent myocardial infarction. METHODS: In the MASTER DAPT trial, 4,579 patients at HBR were randomized after 1 month of dual APT (DAPT) to abbreviated (DAPT stopped and 11 months single APT or 5 months in patients with oral anticoagulants) or nonabbreviated APT (DAPT for minimum 3 months) strategies. Randomization was stratified by acute or recent myocardial infarction at index procedure. Coprimary outcomes at 335 days after randomization were net adverse clinical outcomes events (NACE); major adverse cardiac and cerebral events (MACCE); and type 2, 3, or 5 Bleeding Academic Research Consortium bleeding. CONCLUSIONS: A 1-month DAPT strategy in patients with HBR presenting with an acute or recent myocardial infarction results in similar NACE and MACCE rates and reduces bleedings compared with a nonabbreviated DAPT strategy. (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen [MASTER DAPT]; NCT03023020).
No takes yet. Share an insight, caveat, or question.
Smits et al. (2022) studied this question. A 1-month dual antiplatelet therapy strategy in high bleeding risk patients with myocardial infarction resulted in similar NACE and MACCE rates and reduced bleeding versus nonabbreviated DAPT.
Synapse has enriched 10 related papers. Consider them for comparative context: